ALTG Celebrates

This year the ALTG celebrates its 15^th birthday. The inaugural meeting of the ALTG was held in Sydney in 2004, and the membership has grown from 70 founding members to more than 850 members today. The group has been ably supported by LFA during the 15 years and conducted more than 20 clinical trials. This year also marks 1000 patients recruited to ALTG clinical trials- a fantastic contribution to lung cancer research and improving patient outcomes.

New ALTG Study ILLUMINATE

ALTG Study, ILLUMINATE Study (ALTG 16/009) is now open to recruitment. This is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).